Thioredoxin reductase inactivation as a pivotal mechanism of ifosfamide in cancer therapy

European Journal of Pharmacology

Volumn 579, Issue 1-3, 2008, Pages 66-73

  Wang, Xufang ^a   Zhang, Jinsong ^a   Xu, Tongwen ^a  

^a UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

Author keywords

Cancer; Ifosfamide; Thioredoxin; Thioredoxin reductase

Indexed keywords

IFOSFAMIDE; THIOREDOXIN REDUCTASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASCITES; BLADDER TUMOR; CANCER CHEMOTHERAPY; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INHIBITION; HEPATOMA CELL; KIDNEY TUMOR; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; SOLID TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; ASCITES; CELL CYCLE; CELL PROLIFERATION; G1 PHASE; IFOSFAMIDE; KIDNEY; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICE; THIOREDOXIN-DISULFIDE REDUCTASE; URINARY BLADDER;

EID: 37549006456     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.10.012     Document Type: Article

References (38)

1. Anestal K., and Arnér E.S.J. Rapid induction of cell death by selenium compromised thioredoxin reductase 1 but not by the fully active enzyme containing selenocysteine. J. Biol. Chem. 278 (2003) 15966-15972
2. Arnér E.S.J. Selenium compromised thioredoxin reductase-derived apoptotic proteins (SecTRAPs): potent killers of cancer cells. Free Radic. Res. 40 Suppl. 1 (2006) S51-S51 Meeting Abstract
3. Biaglow J.E., and Miller R.A. The thioredoxin reductase/thioredoxin system - novel redox targets for cancer therapy. Cancer Biol. Ther. 4 (2005) 6-13
4. Bruggemann S.K., Radike K., Braasch K., Hinrichs J., Kisro J., Hagenah W., Peters S.O., and Wagner T. Chloroacetaldehyde: mode of antitumor action of the ifosfamide metabolite. Cancer Chemother. Pharmacol. 57 (2006) 349-356
5. Cenas N., Prast S., Nivinskas H., Sarlauskas J., and Arnér E.S.J. Interactions of nitroaromatic compounds with the mammalian selenoprotein thioredoxin reductase and the relation to induction of apoptosis in human cancer cells. J. Biol. Chem. 281 (2006) 5593-5603
6. Claiborne A. Catalase activity. In: Greenwald R.A. (Ed). CRC Handbook of Methods for Oxygen Radical Research (1985), CRC Press, Boca Raton 283-284
7. Dechant K.L., Brogden R.N., Pilkington T., and Faulds D. Ifosfamide/MESNA. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer. Drugs 42 (1991) 428-467
8. Ellman G.L. Tissue sulfhydryl groups. Arch. Biochem. Biophys. 82 (1959) 70-77
9. Fang J.G., Lu J., and Holmgren A. Thioredoxin reductase is irreversibly modified by curcumin - a novel molecular mechanism for its anticancer activity. J. Biol. Chem. 280 (2005) 25284-25290
10. Furlanut M., and Franceschi L. Pharmacology of ifosfamide. Oncology 65 Suppl 2 (2003) 2-6
11. Ganther H., and Ip C. Thioredoxin reductase activity in rat liver is not affected by supranutritional levels of monomethylated selenium in vivo and is inhibited only by high levels of selenium in vitro. J. Nutr. 131 (2001) 301-304
12. Habig W.H., Pabst M.J., and Jakoby W.B. Glutathione-S-transferases: the first enzymatic step in mercapturic acid formation. J. Biol. Chem. 249 (1974) 7130-7139
13. Holmgren A., and Bjǒrnstedt M. Thioredoxin and thioredoxin reductase. Methods Enzymol. 252 (1995) 199-208
14. Korkmaz A., Yaren H., Topal T., and Oter S. Molecular targets against mustard toxicity: implication of cell surface receptors, peroxynitrite production, and PARP activation. Arch. Toxicol. 80 (2006) 662-670
15. Lee S.M., Crowther D., Scarffe J.H., Dougal M., Elder R.H., Rafferty J.A., and Margison G.P. Cyclophosphamide decreases O6-alkylguanine-DNA alkyltransferase activity in peripheral lymphocytes of patients undergoing bone marrow transplantation. Br. J. Cancer 66 (1992) 331-336
16. Lerch S., Kupfer A., Idle J.R., and Lauterburg B.H. Cerebral formation in situ of S-carboxymethylcysteine after ifosfamide administration to mice: a further clue to the mechanism of ifosfamide encephalopathy. Toxicol. Lett. 161 (2006) 188-194
17. Lind M.J., McGown A.T., Hadfield J.A., Thatcher N., Crowther D., and Fox B.W. The effect of ifosfamide and its metabolites on intracellular glutathione levels in vitro and in vivo. Biochem. Pharmacol. 36 (1989) 1835-1840
18. Lu J., Chew E.H., and Holmgren A. Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 12288-12293
19. Meier T., Allenbacher A., Mueller E., Multhoff G., Botzler C., Wiesnet M., and Issels R. Ifosfamide induced depletion of glutathione in human peripheral blood lymphocytes and protection by MESNA. Anticancer Drugs 5 (1994) 405-409
20. Moore M.J. Clinical pharmacokinetics of cyclophosphamide. Clin. Pharmacokinet. 20 (1991) 194-208
21. Mustacich D., and Powis G. Thioredoxin reductase. Biochem. J. 346 (2000) 1-8
22. Nguyena P., Awwada R.T., Smarta D.D.K., Spitzb D.R., and Giusa D. Thioredoxin reductase as a novel molecular target for cancer therapy. Cancer Lett. 236 (2006) 164-174
23. Nordberg J., and Arnér E.S.J. Reactive oxygen species, antioxidants, and the mammalian thioredoxin system. Free Radic. Biol. Med. 31 (2001) 1287-1312
24. Park Y.S., Fujiwara N., Koh Y.H., Miyamoto Y., Suzuki K., Honke K., and Taniguchi N. Induction of thioredoxin reductase gene expression by peroxynitrite in human umbilical vein endothelial cells. Biol. Chem. 383 (2002) 683-691
25. Park Y.S., Misonou Y., Fujiwar N., Takahashi M., Miyamoto Y., Koh Y.M., Suzuki K., and Taniguch N. Induction of thioredoxin reductase as an adaptive response to acrolein in human umbilical vein endothelial cells. Biochem. Biophys. Res. Commun. 327 (2005) 1058-1065
26. Rotruck J.T., Pope A.L., Ganther H.E., Swanson A.B., Hafeman D.G., and Hoekstra W.G. Selenium: biochemical role as a component of glutathione peroxidase. Science 179 (1973) 588-590
27. Saitoh M., Nishitoh H., Fujii M., Takeda K., Tobiume K., Sawada Y., Kawabata M., Miyazono K., and Ichijo H. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J. 17 (1998) 2596-2606
28. Sakurai A., Nishimoto M., Himeno S., Imura N., Tsujimoto M., Kunimoto M., and Hara S. Transcriptional regulation of thioredoxin reductase 1 expression by cadmium in vascular endothelial cells: role of NF-E2-related factor-2. J. Cell. Physiol. 203 (2005) 529-537
29. Sasada T., Nakamura H., Ueda S., Sato N., Kitaoka Y., Gon Y., Takabayashi A., Spyrou G., Holmgren A., and Yodoi J. Possible involvement of thioredoxin reductase as well as thioredoxin in cellular sensitivity to cis-diamminedichloroplatinum (II). Free Radic. Biol. Med. 27 (1999) 504-514
30. Springate J., Chan K., Lu H., Davies S., and Taub M. Toxicity of ifosfamide and its metabolite chloroacetaldehyde in cultured renal tubule cells. In Vitro Cell. Dev. Biol., Anim. 35 (1999) 314-317
31. Sun Y., Larry W., Oberley W., and Ying L. A simple method for clinical assay of superoxide dismutase. Clin. Chem. 34 (1988) 497-500
32. Wagner T. Ifosfamide clinical pharmacokinetics. Clin. Pharmacokinet. 26 (1994) 439-456
33. Wang X., Zhang J., and Xu T. Cyclophosphamide as a potent inhibitor of tumor thioredoxin reductase in vivo. Toxicol. Appl. Pharmacol. 218 (2007) 88-95
34. Witte A.B., Anestal K., Jerremalm E., Ehrsson H., and Arnér E.S.J. Inhibition of thioredoxin reductase but not of glutathione reductase by the major classes of alkylating and platinum-containing anticancer compounds. Free Radic. Biol. Med. 39 (2005) 696-703
35. Yang X.M., Wu X.L., Choi Y.E., Kern J.C., and Kehrer J.P. Effect of acrolein and glutathione depleting agents on thioredoxin. Toxicology 204 (2004) 209-218
36. Yoo M.H., Xu X.M., Carlson B.A., Gladyshev V.N., and Hatfield D.L. Thioredoxin reductase 1 deficiency reverses tumor phenotype and tumorigenicity of lung carcinoma cells. J. Biol. Chem. 281 (2006) 13005-13008
37. Zaki E., Springate J., and Taub M. Comparative toxicity of ifosfamide metabolites and protective effect of MESNA and amifostine in cultured renal tubule cells. Toxicol. In Vitro 17 (2003) 397-402
38. Zhang J., Tian Q., Chan Y.S., Li S.C., Zhou S., Duan W., and Zhu Y.Z. Metabolism and transport of oxazaphosphorines and the clinical implications. Drug Metab. Rev. 37 (2005) 611-703